Participants 213 260 3
patients with bone marrow transplantation (BMT)
Participants 322 345 3
patients undergoing BMT
Participants 347 584 6
METHODS For evaluation of GLN in BMT, 66 patients with 43 hematologic and 23 solid malignancies (21 breast carcinomas), were randomized, double-blinded, to either oral GLN (n = 35) or glycine-control (GLY) (n = 31), 10 g three times dail
Participants 761 799 4
Patients with hematologic malignancies
Participants 956 997 3
Patients with solid malignancies (n = 23)
